A New Age of
CNS Solutions
Our Projects
Cloud Analytics Modernization
I'm a paragraph. Click here to add your own text and edit me. It’s easy. Just click “Edit Text” or double click me to add your own content and make changes to the font. I’m a great place for you to tell a story and let your users know a little more about you.
A Staggered approach to IP creation
We Combine the power of psychedelics with our development capabilities and collaborations with top tear research institutes to create a robust pipeline of new indications, novel formulations and new third generation molecules. This creates a staggered approach to ensure longevity and innovation. Aging population, Covid-19 and a global need for opioid replacements makes our mission one of the most needed in the coming future.
University Of California
New Neurological indications (use case IP \ Formulation IP)
The surge in psychedelic research and wide acceptance from regulators and the medical community opens the opportunity to promote human clinical trials in new previously un explored indications. Getting real world clinical efficacy data is an un paralleled opportunity to discover new neurological indications affected by psychedelic treatment as well as educate our R&D efforts to be able to create better second generation solutions.
Drug Delivery (Delivery \ CoM IP)
IMIO’s Brain Targeted Liposome System (BTLs) was developed together with the Israel Institute of Technology to enable targeted drug delivery across the Blood Brain Barrier BBB. It has the ability to actively transport drugs through the BBB and into the brain. Extensive pre-clinical work has demonstrated BBB penetration ability. Targeted delivery of medications to the brain brings the possibility to reduce side effects, reduce needed concentrations and manipulate the drug kinetics.
The Hebrew
University
Of Jerusalem
Drug Discovery (CoM IP)
Leveraging pre-clinical and clinical research data on mode of action and various effects of known psychedelic drugs (i.e. 5-MeO-DMT or LSD), IMIO in collaboration with Hebrew university's Institute for Drug Research to develop next generation of new chemical entities (NCE's) leveraging on Hebrew University's "Multi Targeting drug discovery platform"
Successful NCEs deliver better care for patients and deliver the highest rate of return for investment in R&D and regulatory.
High Impact Chronic Pain
Fibromyalgia is a disorder characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory and mood issues. Researchers believe that fibromyalgia amplifies painful sensations by affecting the way the brain processes pain signals.Symptoms sometimes begin after a physical trauma, surgery, infection or significant psychological stress. In other cases, symptoms gradually accumulate over time with no single triggering event. Women are more likely to develop fibromyalgia than are men. Many people who have fibromyalgia also have tension headaches, temporomandibular joint (TMJ) disorders, irritable bowel syndrome, anxiety and depression.
20%
Estimated US Patients
20%
Of US Population
3B$
Treatment Market
Fibromyalgia
Fibromyalgia is a disorder characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory and mood issues. Researchers believe that fibromyalgia amplifies painful sensations by affecting the way the brain processes pain signals.Symptoms sometimes begin after a physical trauma, surgery, infection or significant psychological stress. In other cases, symptoms gradually accumulate over time with no single triggering event. Women are more likely to develop fibromyalgia than are men. Many people who have fibromyalgia also have tension headaches, temporomandibular joint (TMJ) disorders, irritable bowel syndrome, anxiety and depression.
10M
Estimated US Patients
3-6%
World Population
3B$
Treatment Market
Cluster Headaches
Cluster headaches, which occur in cyclical patterns or cluster periods, are one of the most painful types of headache. A cluster headache commonly awakens you in the middle of the night with intense pain in or around one eye on one side of your head. Bouts of frequent attacks, known as cluster periods, can last from weeks to months, usually followed by remission periods when the headaches stop. A cluster period generally lasts for several weeks to months. The starting date and the duration of each cluster period might be consistent from period to period. Most people have episodic cluster headaches. In episodic cluster headaches, the headaches occur for one week to a year, followed by a pain-free remission period lasting 3 months or longer before another cluster headache develops.
10M
Estimated US Patients
3-6%
World Population
1B$
Treatment Market
Chronic Fatigue Syndrome (CFS)
Chronic fatigue syndrome (CFS) is a complicated disorder characterized by extreme fatigue that lasts for at least six months and that can't be fully explained by an underlying medical condition. The fatigue worsens with physical or mental activity, but doesn't improve with rest. Anyone can get CFS. While most common in people between 40 and 60 years old, the illness affects children, adolescents, and adults of all ages. Among adults, women are affected more often than men. The cause of CFS is unknown, although there are many theories ranging from viral infections to psychological stress. Some experts believe chronic fatigue syndrome might be triggered by a combination of factors.
20M
Estimated Patients
75%
Unable To Work
24B$
US Economic Burden
Mild Cognitive Impairment (MCI)
Mild cognitive impairment (MCI) is the stage between the expected decline in memory and thinking that happens with age and the more serious decline of dementia. MCI may include problems with memory, language or judgment. People with MCI may be aware that their memory or mental function has "slipped." Family and close friends also may notice changes but these changes aren't bad enough to impact daily life or affect usual activities. MCI may increase the risk of dementia caused by Alzheimer's disease or other brain disorders.
12M
Estimated US Patients
6-15%
Will Develop AD
2B$
Treatment Market